You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCalcitriol
Accession NumberDB00136  (NUTR00003, APRD00246)
TypeSmall Molecule
GroupsApproved, Nutraceutical
DescriptionCalcitriol or 1,25-dihydroxycholecalciferol (abbreviated 1,25-(OH)2-D3) is the active form of vitamin D found in the body (vitamin D3). Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis). It is produced in the kidneys via 25-hydroxyvitamin D-1 α-hydroxylase by conversion from 25-hydroxycholecalciferol (calcidiol). This is stimulated by a decrease in serum calcium, phosphate (PO43−) and parathyroid hormone (PTH) levels. It regulates calcium levels by increasing the absorption of calcium and phosphate from the gastrointestinal tract, increasing calcium and phosphate reabsorption in the kidneys and inhibiting the release of PTH. Calcitriol is also commonly used as a medication in the treatment of hypocalcemia and osteoporosis.
Structure
Thumb
Synonyms
(1alpha,3beta,5Z,7e)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7e)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(5Z,7e)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
1-alpha-25-Dihydroxyvitamin D3
1,25-DHCC
1,25-dihydroxycholecalciferol
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D3
1alpha,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
1α,25(OH)2D3
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
Calcijex
Calcitriol
Calcitriolum
Decostriol
Rocaltrol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalcijexSolution2 mcgIntravenousAbbvie Corporation1990-12-31Not applicableCanada
CalcijexInjection, solution1 ug/mLIntravenousAbb Vie Inc.2010-06-01Not applicableUs
CalcijexSolution1 mcgIntravenousAbbvie Corporation1990-12-31Not applicableCanada
CalcitriolSolution1 ug/mLOralRanbaxy Pharmaceuticals Inc.2009-08-26Not applicableUs
CalcitriolOintment3 ug/gTopicalPerrigo New York Inc2012-03-08Not applicableUs
CalcitriolCapsule.25 ug/1OralDispensing Solutions, Inc.2009-08-26Not applicableUs
CalcitriolCapsule.25 ug/1OralRanbaxy Pharmaceuticals Inc.2009-08-26Not applicableUs
CalcitriolCapsule.25 ug/1OralCarilion Materials Management2009-08-26Not applicableUs
CalcitriolCapsule.25 ug/1OralAphena Pharma Solutions Tennessee, Llc2009-08-26Not applicableUs
CalcitriolCapsule.5 ug/1OralRanbaxy Pharmaceuticals Inc.2009-08-26Not applicableUs
Calcitriol InjectionSolution1 mcgIntravenousFresenius Kabi Canada Ltd2003-07-07Not applicableCanada
Calcitriol Injection USPSolution1 mcgIntravenousSterimax Inc2015-03-27Not applicableCanada
Calcitriol Injection USPSolution2 mcgIntravenousSterimax Inc2015-04-16Not applicableCanada
Calcitriol-odanCapsule0.5 mcgOralOdan Laboratories Ltd2014-10-10Not applicableCanada
Calcitriol-odanCapsule0.25 mcgOralOdan Laboratories Ltd2014-10-10Not applicableCanada
RocaltrolCapsule, gelatin coated.25 ug/1OralAphena Pharma Solutions Tennessee, Inc.2009-08-10Not applicableUs
RocaltrolCapsule, gelatin coated.25 ug/1OralValidus Pharmaceuticals LLC2009-08-10Not applicableUs
RocaltrolCapsule, gelatin coated.5 ug/1OralKAISER FOUNDATION HOSPITALS2010-06-04Not applicableUs
RocaltrolCapsule, gelatin coated.5 ug/1OralValidus Pharmaceuticals LLC2009-08-10Not applicableUs
RocaltrolCapsule, gelatin coated.25 ug/1OralKAISER FOUNDATION HOSPITALS2010-08-09Not applicableUs
RocaltrolSolution1 ug/mLOralValidus Pharmaceuticals LLC2009-07-23Not applicableUs
Rocaltrol Cap 0.25mcgCapsule0.25 mcgOralHoffmann La Roche Limited1979-12-31Not applicableCanada
Rocaltrol Cap 0.5mcgCapsule0.5 mcgOralHoffmann La Roche Limited1979-12-31Not applicableCanada
Rocaltrol Oral Solution 1mcg/mlSolution1 mcgOralHoffmann La Roche Limited1992-12-312013-06-24Canada
SilkisOintment3 mcgTopicalGalderma Canada Inc2010-04-09Not applicableCanada
VecticalOintment3 ug/gTopicalGalderma Laboratories, L.P.2009-02-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalcitriolSolution1 ug/mLOralWest Ward Pharmaceuticals Corp.2003-07-18Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralHeritage Pharmaceuticals Inc2013-05-29Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralGolden State Medical Supply, Inc.2014-12-26Not applicableUs
CalcitriolInjection1 ug/mLIntravenousWest ward Pharmaceutical Corp2006-02-08Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralTeva Pharmaceuticals Usa, Inc.2001-10-152017-07-31Us
CalcitriolCapsule, liquid filled.25 ug/1OralPhysicians Total Care, Inc.2005-12-02Not applicableUs
CalcitriolCapsule.5 ug/1OralStrides Arcolab Limited2015-01-06Not applicableUs
CalcitriolInjection1 ug/mLIntravenousAkorn, Inc.2013-03-22Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralTeva Pharmaceuticals Usa, Inc.2016-08-25Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralHeritage Pharmaceuticals Inc2013-05-29Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralGolden State Medical Supply, Inc.2014-12-26Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralKAISER FOUNDATION HOSPITALS2015-12-03Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralTeva Pharmaceuticals Usa, Inc.2001-10-152017-10-31Us
CalcitriolInjection, solution1 mg/mLIntravenousPhysicians Total Care, Inc.2011-05-17Not applicableUs
CalcitriolCapsule.25 ug/1OralAmerican Health Packaging2012-03-012016-11-30Us
CalcitriolInjection1 ug/mLIntravenousAkorn, Inc.2011-10-14Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralTeva Pharmaceuticals Usa, Inc.2016-07-01Not applicableUs
CalcitriolCapsule.25 ug/1OralAphena Pharma Solutions Tennessee, Llc2006-03-27Not applicableUs
CalcitriolInjection, solution1 ug/mLIntravenousFresenius Kabi USA, LLC2003-05-29Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralKAISER FOUNDATION HOSPITALS2015-12-03Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralCardinal Health2009-10-29Not applicableUs
CalcitriolCapsule.25 ug/1OralWest Ward Pharmaceuticals Corp.2006-03-27Not applicableUs
CalcitriolInjection2 ug/mLIntravenousAkorn, Inc.2011-10-14Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralAphena Pharma Solutions Tennessee, Llc2013-05-29Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralPhysicians Total Care, Inc.2010-03-01Not applicableUs
CalcitriolCapsule.25 ug/1OralStrides Arcolab Limited2015-01-06Not applicableUs
CalcitriolInjection, solution1 ug/mLIntravenousAmerican Regent, Inc.2005-03-14Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralCardinal Health2009-10-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Calcitriol Oral SolutionRoxane
DecostriolMibe Jena (Germany), Jesalis (Hong Kong, Thailand)
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIFXC9231JVH
CAS number32222-06-3
WeightAverage: 416.6365
Monoisotopic: 416.329045274
Chemical FormulaC27H44O3
InChI KeyGMRQFYUYWCNGIN-NKMMMXOESA-N
InChI
InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
IUPAC Name
(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
SMILES
C[[email protected]](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[[email protected]](O)C1=C
Pharmacology
IndicationUsed to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
Structured Indications
PharmacodynamicsCalcitriol, a pharmaceutical form of vitamin D, has anti-osteoporotic, immunomodulatory, anticarcinogenic, antipsoriatic, antioxidant, and mood-modulatory activities. Calcitriol has been found to be effective in the treatment of psoriasis when applied topically. Calcitriol has been found to induce differentiation and/or inhibit cell proliferation in a number of malignant cell lines including human prostate cancer cells. Vitamin D deficiency has long been suspected to increase the susceptibility to tuberculosis. The active form of calcitriol, 1,25-(OH)2-D3, has been found to enhance the ability of mononuclear phagocytes to suppress the intracellular growth of Mycobacterium tuberculosis. 1,25-(OH)2-D3 has demonstrated beneficial effects in animal models of such autoimmune diseases as rheumatoid arthritis. It has also been found to induce monocyte differentiation and to inhibit lymphocyte proliferation and production of cytokines, including interleukin IL-1 and IL-2, as well as to suppress immunoglobulin secretion by B lymphocytes. Vitamin D appears to demonstrate both immune-enhancing and immunosuppressive effects.
Mechanism of actionThe mechanism of action of calcitriol in the treatment of psoriasis is accounted for by their antiproliferative activity for keratinocytes and their stimulation of epidermal cell differentiation. The anticarcinogenic activity of the active form of Calcitriol appears to be correlated with cellular vitamin D receptor (VDR) levels. Vitamin D receptors belong to the superfamily of steroid-hormone zinc-finger receptors. VDRs selectively bind 1,25-(OH)2-D3 and retinoic acid X receptor (RXR) to form a heterodimeric complex that interacts with specific DNA sequences known as vitamin D-responsive elements. VDRs are ligand-activated transcription factors. The receptors activate or repress the transcription of target genes upon binding their respective ligands. It is thought that the anticarcinogenic effect of Calcitriol is mediated via VDRs in cancer cells. The immunomodulatory activity of calcitriol is thought to be mediated by vitamin D receptors (VDRs) which are expressed constitutively in monocytes but induced upon activation of T and B lymphocytes. 1,25-(OH)2-D3 has also been found to enhance the activity of some vitamin D-receptor positive immune cells and to enhance the sensitivity of certain target cells to various cytokines secreted by immune cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Vitamin D3 receptorProteinyes
antagonist
HumanP11473 details
Related Articles
AbsorptionRapidly absorbed from the intestine.
Volume of distributionNot Available
Protein binding99.9%
Metabolism

The first pathway involves 24-hydroxylase activity in the kidney; this enzyme is also present in many target tissues which possess the vitamin D receptor such as the intestine. The end product of this pathway is a side chain shortened metabolite, calcitroic acid. The second pathway involves the conversion of calcitriol via the stepwise hydroxylation of carbon-26 and carbon-23, and cyclization to yield ultimately 1a,25R(OH)2-26,23S-lactone D3. The lactone appears to be the major metabolite circulating in humans.

SubstrateEnzymesProduct
Calcitriol
Not Available
Calcitroic acidDetails
Route of eliminationEnterohepatic recycling and biliary excretion of calcitriol occur. The metabolites of calcitriol are excreted primarily in feces. Cumulative excretion of radioactivity on the sixth day following intravenous administration of radiolabeled calcitriol averaged 16% in urine and 49% in feces.
Half life5-8 hours
Clearance
  • 15.3 mL/hr/kg [pediatric patients (age range: 1.8 to 16 years) undergoing peritoneal dialysis receiving dose of 10.2 ng/kg (SD 5.5 ng/kg) for 2 months]
ToxicityLD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg; Overdose evident in elevated blood calcium levels causing symptoms of anorexia, nausea and vomiting, polyuria, polydipsia, weakness, pruritus, and nervousness, potentially with irreversible calcification of soft tissue in the kidney and liver.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 5-androstenedione.Experimental, Illicit
AcetyldigitoxinCalcitriol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AlclometasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Alclometasone.Approved
AldosteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Aldosterone.Experimental
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Alfacalcidol.Approved, Nutraceutical
Aluminum hydroxideThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcitriol.Approved
AmcinonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Amcinonide.Approved
AmiodaroneThe metabolism of Calcitriol can be decreased when combined with Amiodarone.Approved, Investigational
AnecortaveThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Anecortave.Investigational
AnvirzelCalcitriol may increase the arrhythmogenic activities of Anvirzel.Investigational
AprepitantThe serum concentration of Calcitriol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Calcitriol.Approved, Investigational
AtazanavirThe metabolism of Calcitriol can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Calcitriol can be decreased when combined with Atomoxetine.Approved
BeclomethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Beclomethasone.Investigational
Beclomethasone dipropionateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypercalcemic activities of Calcitriol.Approved
BetamethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BexaroteneThe serum concentration of Calcitriol can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Calcitriol can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Calcitriol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Calcitriol can be decreased when it is combined with Bosentan.Approved, Investigational
BudesonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Budesonide.Approved
CalcidiolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Calcipotriol.Approved
CalciumThe risk or severity of adverse effects can be increased when Calcium is combined with Calcitriol.Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcitriol.Approved
Calcium carbonateThe risk or severity of adverse effects can be increased when Calcium carbonate is combined with Calcitriol.Approved
Calcium ChlorideThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcitriol.Approved
Calcium citrateThe risk or severity of adverse effects can be increased when Calcium citrate is combined with Calcitriol.Approved
Calcium glubionateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcitriol.Approved
Calcium GluceptateThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcitriol.Approved
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcitriol.Approved, Vet Approved
CarbamazepineThe metabolism of Calcitriol can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Calcitriol can be increased when it is combined with Ceritinib.Approved
ChlorothiazideChlorothiazide may increase the hypercalcemic activities of Calcitriol.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypercalcemic activities of Calcitriol.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineThe serum concentration of Calcitriol can be decreased when it is combined with Cholestyramine.Approved
CiclesonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Ciclesonide.Approved, Investigational
ClarithromycinThe metabolism of Calcitriol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Calcitriol can be decreased when combined with Clemastine.Approved
ClobetasolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clobetasol.Investigational
Clobetasol propionateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clobetasol propionate.Approved
ClocortoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clocortolone.Approved
ClotrimazoleThe metabolism of Calcitriol can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Calcitriol can be decreased when combined with Cobicistat.Approved
ColesevelamThe serum concentration of Calcitriol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Calcitriol can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Calcitriol can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Cortisone acetate.Approved
CrizotinibThe metabolism of Calcitriol can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Calcitriol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Calcitriol can be decreased when it is combined with Dabrafenib.Approved
DanazolDanazol may increase the hypercalcemic activities of Calcitriol.Approved
DarunavirThe metabolism of Calcitriol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Calcitriol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Calcitriol can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Calcitriol can be decreased when combined with Delavirdine.Approved
DeslanosideCalcitriol may increase the arrhythmogenic activities of Deslanoside.Approved
DesoximetasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoximetasone.Approved
Desoxycorticosterone acetateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone isonicotinate.Vet Approved
DiflorasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Diflorasone.Approved
DifluocortoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Difluocortolone.Approved
DifluprednateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Difluprednate.Approved
DigitoxinCalcitriol may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinCalcitriol may increase the arrhythmogenic activities of Digoxin.Approved
DihydroergotamineThe metabolism of Calcitriol can be decreased when combined with Dihydroergotamine.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Dihydrotachysterol.Approved
DiltiazemThe metabolism of Calcitriol can be decreased when combined with Diltiazem.Approved
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Doxercalciferol.Approved
DoxycyclineThe metabolism of Calcitriol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Calcitriol can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Calcitriol can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Calcitriol can be decreased when it is combined with Enzalutamide.Approved
EquileninThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Equilenin.Experimental
EquilinThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Equilin.Approved
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Ergocalciferol.Approved, Nutraceutical
ErythromycinThe metabolism of Calcitriol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Calcitriol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone.Approved
Estrone sulfateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone sulfate.Approved
EtravirineThe serum concentration of Calcitriol can be decreased when it is combined with Etravirine.Approved
fluasteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with fluasterone.Investigational
FluconazoleThe metabolism of Calcitriol can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fludrocortisone.Approved
FlumethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flumethasone.Approved, Vet Approved
FlunisolideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinonide.Approved, Investigational
FluocortoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocortolone.Approved, Withdrawn
FluorometholoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluorometholone.Approved
FluprednideneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluprednisolone.Approved
FlurandrenolideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flurandrenolide.Approved
Fluticasone furoateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone furoate.Approved
Fluticasone PropionateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Calcitriol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Calcitriol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Calcitriol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Calcitriol can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Calcitriol can be increased when it is combined with Fusidic Acid.Approved
HE3286The therapeutic efficacy of Calcitriol can be decreased when used in combination with HE3286.Investigational
HydrochlorothiazideHydrochlorothiazide may increase the hypercalcemic activities of Calcitriol.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Calcitriol.Approved, Illicit
HydrocortisoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypercalcemic activities of Calcitriol.Approved
IdelalisibThe serum concentration of Calcitriol can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Calcitriol can be decreased when combined with Imatinib.Approved
IndapamideIndapamide may increase the hypercalcemic activities of Calcitriol.Approved
IndinavirThe metabolism of Calcitriol can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Calcitriol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Calcitriol can be decreased when combined with Isradipine.Approved
IstaroximeThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Istaroxime.Investigational
ItraconazoleThe metabolism of Calcitriol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Calcitriol can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Calcitriol can be decreased when combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Calcitriol can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Calcitriol can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Calcitriol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Calcitriol can be increased when combined with Lumacaftor.Approved
Magnesium hydroxideThe serum concentration of Magnesium hydroxide can be increased when it is combined with Calcitriol.Approved
Magnesium oxideThe serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol.Approved
Magnesium salicylateThe serum concentration of Magnesium salicylate can be increased when it is combined with Calcitriol.Approved
Magnesium SulfateThe serum concentration of Magnesium Sulfate can be increased when it is combined with Calcitriol.Approved, Vet Approved
ME-609The therapeutic efficacy of Calcitriol can be decreased when used in combination with ME-609.Investigational
MedrysoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Medrysone.Approved
MelengestrolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Melengestrol.Vet Approved
MethyclothiazideMethyclothiazide may increase the hypercalcemic activities of Calcitriol.Approved
MethylprednisoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneMetolazone may increase the hypercalcemic activities of Calcitriol.Approved
MifepristoneThe serum concentration of Calcitriol can be increased when it is combined with Mifepristone.Approved, Investigational
Mineral oilThe serum concentration of Calcitriol can be decreased when it is combined with Mineral oil.Approved
MitotaneThe serum concentration of Calcitriol can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Calcitriol can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Mometasone.Approved, Vet Approved
NafcillinThe serum concentration of Calcitriol can be decreased when it is combined with Nafcillin.Approved
NCX 1022The therapeutic efficacy of Calcitriol can be decreased when used in combination with NCX 1022.Investigational
NefazodoneThe metabolism of Calcitriol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Calcitriol can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Calcitriol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Calcitriol can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Calcitriol can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Calcitriol.Approved
OlaparibThe metabolism of Calcitriol can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Oleoyl estrone.Investigational
OrlistatThe serum concentration of Calcitriol can be decreased when it is combined with Orlistat.Approved, Investigational
OsimertinibThe serum concentration of Calcitriol can be increased when it is combined with Osimertinib.Approved
OuabainCalcitriol may increase the arrhythmogenic activities of Ouabain.Approved
PalbociclibThe serum concentration of Calcitriol can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Paramethasone.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Paricalcitol.Approved, Investigational
PentobarbitalThe metabolism of Calcitriol can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Calcitriol can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Calcitriol can be increased when combined with Phenytoin.Approved, Vet Approved
PolythiazidePolythiazide may increase the hypercalcemic activities of Calcitriol.Approved
PosaconazoleThe metabolism of Calcitriol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prasterone.Approved, Nutraceutical
PrednicarbateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednicarbate.Approved
PrednisoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregnenoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Pregnenolone.Experimental
PrimidoneThe metabolism of Calcitriol can be increased when combined with Primidone.Approved, Vet Approved
QuinethazoneQuinethazone may increase the hypercalcemic activities of Calcitriol.Approved
RanolazineThe metabolism of Calcitriol can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Calcitriol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Calcitriol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Calcitriol can be increased when combined with Rifapentine.Approved
RimexoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Rimexolone.Approved
RitonavirThe metabolism of Calcitriol can be decreased when combined with Ritonavir.Approved, Investigational
SaquinavirThe metabolism of Calcitriol can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Calcitriol.Approved
SevelamerThe serum concentration of Calcitriol can be decreased when it is combined with Sevelamer.Approved
SildenafilThe metabolism of Calcitriol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Calcitriol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Calcitriol can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Calcitriol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Calcitriol can be increased when it is combined with Stiripentol.Approved
SucralfateThe serum concentration of Sucralfate can be increased when it is combined with Calcitriol.Approved
SulfisoxazoleThe metabolism of Calcitriol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Calcitriol can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Calcitriol can be decreased when combined with Telithromycin.Approved
TiclopidineThe metabolism of Calcitriol can be decreased when combined with Ticlopidine.Approved
TixocortolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Tixocortol.Approved
TocilizumabThe serum concentration of Calcitriol can be decreased when it is combined with Tocilizumab.Approved
TriamcinoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypercalcemic activities of Calcitriol.Approved, Vet Approved
VenlafaxineThe metabolism of Calcitriol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Calcitriol can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Calcitriol can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Calcitriol can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Raymond E. Conrow, “Process for preparation of calcitriol lactone and related intermediates.” U.S. Patent US5457245, issued April, 1994.

US5457245
General ReferencesNot Available
External Links
ATC CodesA11CC04D05AX03
AHFS Codes
  • 88:16.00
PDB EntriesNot Available
FDA labelDownload (39.2 KB)
MSDSDownload (74.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.8524
Caco-2 permeable+0.7812
P-glycoprotein substrateSubstrate0.7843
P-glycoprotein inhibitor INon-inhibitor0.6065
P-glycoprotein inhibitor IINon-inhibitor0.6073
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8367
CYP450 2D6 substrateNon-substrate0.9022
CYP450 3A4 substrateSubstrate0.7506
CYP450 1A2 substrateNon-inhibitor0.9033
CYP450 2C9 inhibitorNon-inhibitor0.8354
CYP450 2D6 inhibitorNon-inhibitor0.9495
CYP450 2C19 inhibitorNon-inhibitor0.7796
CYP450 3A4 inhibitorNon-inhibitor0.813
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6175
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9274
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity5.1352 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8734
hERG inhibition (predictor II)Non-inhibitor0.8579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Validus pharmaceuticals llc
  • Abbott laboratories hosp products div
  • Akorn inc
  • App pharmaceuticals llc
  • Fresenius medical care north america
  • Genix therapeutics inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Lyne laboratories inc
  • Teva parenteral medicines inc
  • Galderma laboratories lp
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1 ug/mL
SolutionIntravenous1 mcg
SolutionIntravenous2 mcg
CapsuleOral.25 ug/1
CapsuleOral.5 ug/1
Capsule, liquid filledOral.25 ug/1
Capsule, liquid filledOral.5 ug/1
InjectionIntravenous1 ug/mL
InjectionIntravenous2 ug/mL
Injection, solutionIntravenous1 mg/mL
Capsule, gelatin coatedOral.25 ug/1
Capsule, gelatin coatedOral.5 ug/1
SolutionOral1 ug/mL
CapsuleOral0.25 mcg
CapsuleOral0.5 mcg
SolutionOral1 mcg
OintmentTopical3 mcg
OintmentTopical3 ug/g
Prices
Unit descriptionCostUnit
Calcijex 2 mcg/ml19.38USD ml
Calcijex 1 mcg/ml ampul14.7USD ml
Calcijex 1 mcg/ml10.68USD ml
Calcitriol 1 mcg/ml ampul6.0USD ml
Vectical 3 mcg/g ointment4.68USD g
Rocaltrol 0.5 mcg capsule2.02USD capsule
Calcitriol 0.5 mcg capsule1.97USD capsule
Rocaltrol 0.25 mcg capsule1.46USD capsule
Calcitriol 0.25 mcg capsule1.45USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6051567 Yes2000-02-022020-02-02Us
US6265392 Yes2000-02-022020-02-02Us
US6274169 Yes2000-02-022020-02-02Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point113-114Uskokovic, M.R., Narwid, T.A., lacobelli, J.A. and Baggiolini, E.; U.S. Patent 3,993,675; November 23, 1976; assigned to Hoffmann-La Roche, Inc.
water solubilityInsolubleNot Available
logP5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00667 mg/mLALOGPS
logP5.51ALOGPS
logP4.35ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)14.39ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity126.53 m3·mol-1ChemAxon
Polarizability51.02 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing 8 isoprene units.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassTriterpenoids
Direct ParentTriterpenoids
Alternative Parents
Substituents
  • Polycyclic triterpenoid
  • Triterpenoid
  • Steroid
  • Cyclohexanol
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary alcohol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.
Gene Name:
VDR
Uniprot ID:
P11473
Molecular Weight:
48288.64 Da
References
  1. Reinhart GA: Vitamin D analogs: novel therapeutic agents for cardiovascular disease? Curr Opin Investig Drugs. 2004 Sep;5(9):947-51. [PubMed:15503649 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxidoreductase activity
Specific Function:
Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23-hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product.
Gene Name:
CYP24A1
Uniprot ID:
Q07973
Molecular Weight:
58874.695 Da
References
  1. Schuster I: Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99. doi: 10.1016/j.bbapap.2010.06.022. Epub 2010 Jul 7. [PubMed:20619365 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE: Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 Jan;69(1):56-65. Epub 2005 Oct 5. [PubMed:16207822 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54